Coming May 2025
Get Early Access
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
57 employees
Genome Insight: Expert in whole genome sequence analysis and interpretation.
HQ
Founded
2020
Genome Insight is dedicated to advancing the field of genomics through comprehensive whole genome sequence (WGS) analysis and interpretation. The company offers cutting-edge genomic solutions aimed at improving personalized medicine, disease diagnosis, and therapeutic strategies. Their market focus includes healthcare providers, research institutions, and pharmaceutical companies.
Genome Insight has made significant strides in the genomics industry, contributing to numerous research projects and clinical applications. Their expertise in WGS has positioned them as a key player in personalized medicine, enhancing the ability to tailor treatments based on individual genetic profiles.
Operating Status
Active
Ownership Type(s)
Private
Main Product(s)
Genome Sequencing
Technology
Analytics
Tags
Biotech, Data
Model Types
Data Information, Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Genome Insight founded?
Genome Insight was founded in 2020.
Where is Genome Insight's headquarters located?
Genome Insight's headquarters is located in San Diego, CA, US.
When was Genome Insight's last funding round?
Genome Insight's most recent funding round was for $23M (USD) in November 2023.
How many employees does Genome Insight have?
Genome Insight has 57 employees as of Feb 5, 2024.
How much has Genome Insight raised to-date?
As of July 05, 2023, Genome Insight has raised a total of $52.7M (USD) since Nov 1, 2023.
Add Comparison
Total Raised to Date
$52.7M
USD
Last Update Nov 1, 2023
Last Deal Details
$23M
USD
Nov 1, 2023
Series B
Current Employees
57
Last updated: Feb 5, 2024
No location information available for this company.
Locations
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts